Lipum publishes an information memorandum in connection with the company’s forthcoming rights issue

IMPORTANT INFORMATION

Due to legal restrictions, the information on this part of Lipum’s website is not accessible to certain persons. We kindly ask you to review the following information and provide the following confirmation each time you wish to access these websites. Please note that the terms set out below may be altered or updated and therefore it is important that you review them each time you visit this page.

The information contained in this section of Lipum’s website is not intended for, and must not be accessed by, or distributed or disseminated, directly or indirectly, in whole or in part, to persons resident or physically present in the United States of America (including its territories and possessions, any state of the United States and the District of Columbia) (the “United States”), Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or any other jurisdiction where such action is wholly or partially subject to legal restrictions, or would require prospectuses, registration or other measures than those required by Swedish law. The information on the websites does not constitute any offer regarding subscription rights, paid subscribed shares or shares in Lipum (“Securities”) to any person in said jurisdictions. The information on the websites may not be forwarded or reproduced in such a manner that contravenes such restrictions or gives cause to such requirements.

No Securities have been or will be registered under the United States Securities Act of 1933, as amended (the “Securities Act”) or the securities legislation of any state or other jurisdiction in the United States and thus the Securities may not be offered, subscribed for, exercised, pledged, sold, resold, allotted, delivered or otherwise transferred, directly or indirectly, in or into the United States. All offers and sales of securities in connection with any rights offer by the Company will be made outside of the United States and in reliance on, and in compliance with, Regulation S under the Securities Act. There will be no public offering in the United States.

The information contained in this section of the website of Lipum does not constitute a prospectus for the purposes of (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the “Prospectus Regulation”) or the Commission Delegated Regulation (EU) 2019/980 of 14 March 2019. The information contained in this section of the website has also not been subject to revision by the Swedish Financial Supervisory Authority in accordance with the Prospectus Regulation.

To access the information contained in this section of Lipum’s website, all persons must first ensure that they are not subject to legal restrictions that limit their right to access the information on this part of Lipum’s website.

We therefore kindly ask you to confirm that you are resident and physically present outside the United States, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa and any other jurisdiction where such action is wholly or partially subject to legal restrictions, or would require prospectuses, registration or other measures than those required by Swedish law, and are entitled to access the information on these websites without being subject to restrictions in any law or other regulations and without any further action being required by Lipum. We also kindly ask you to confirm that you have read the information, conditions and restrictions above, and confirm that you agree to comply with these.